Dividend Growth Forum

Full Version: What Did You Buy Today?
You're currently viewing a stripped down version of our content. View the full version with proper formatting.
Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767

crimsonghost747

Non-GAAP is a dangerous thing to look at since pretty much anything goes for an "adjustment" these days, and I constantly see companies where the non-GAAP is by default higher than the GAAP one. I get that sometimes there is a need for adjustments (such as mergers etc) but more often than not I see companies constantly having these same adjustments in there, and surprisingly almost always the non-GAAP EPS is higher than the GAAP EPS.

There is a reason for GAAP. And I find it significantly better to look at the GAAP EPS and then look at the adjustments separately to see if the things adjusted for are truly one time items or not. Take one of the greatest DGI companies out there: JNJ. The non-GAAP EPS is always higher than the GAAP EPS and things such as legal costs are being adjusted for, every single year. As if JNJ being involved in a lawsuit would be something of a irregular "once in a decade" thing. No, getting sued for a company like JNJ is part of business and there will always be legal cases against them, there will be legal fees every single year. All those lawyers, other legal fees, and settlements etc are being paid by JNJ all the time, yet conveniently they cease to exist when you look at the non-GAAP numbers. It's "one time items" after all. Big Grin

Same kinda goes for "forward EPS". It's just an estimate by an analyst. And if we were convinced that analysts are right more often than not then we wouldn't be on this forum and the majority of our portfolio would be compromised of all sorts of actively managed funds.
[quote pid='27266' dateline='1625931839']
(07-10-2021, 09:41 AM)ken-do-nim Wrote: [ -> ]
(07-10-2021, 08:24 AM)EricL Wrote: [ -> ]Here are stocks that I currently show as near or below fair value from my portfolio.
ABBV, AMP, BDX, BMY, D, EOG, FLO, KMI, LMT, MO, PM, SRE, T, WBA

ABBV's P/E ratio is at 41.09; still high I think.

Depending on if you are using GAAP or non-GAAP earnings, trailing or projected earnings.

It's expected to earn $12.55 in non-GAAP in 2021, giving it a PE of 9.3.

It's expected to earn $7.67 in GAAP in 2021, giving it a PE of 15.2.

It had $10.56 in non-GAAP earnings in 2020, giving a PE of 11.0.

It earned $2.72 in GAAP in 2020, giving a PE of 42.9.

Three out of four measures show it trading at a substantial discount to the market, not to mention the near 4.5% yield.
[/quote]
Feel free to contradict me Eric.

Ken,

You seem willing to put in the analytics time and you should if you grow largish holdings in individual stocks.  This is a place to spend some time because a PE without context is just a number.

ABBV PE vs MSFT PE vs a REIT PE really is meaningless to an investor.  S&P500 PE numbers 2005-2015 vs today has some relevance.  It's highly likely historicals won't be completely ignored forever.  It's not a given 1990 will ever matter again though.  Don't hold you breath waiting for UTE PEs to return to 1980 levels.  The game changed.  1999 tech PEs were and still are nuts.  There are limits to valuation insanity that can't be explained away.  There is always context to consider.

Healthcare/pharma PEs would be a good place to learn.  First of all the entire sector is undervalued vs SPY.  There is risk they will be targeted by politicians from both parties.  That may or may not last for years.  Almost all the major pharmas are being discounted some for that.  As an ABBV shareholder you should be very aware their flagship drug comes off patent in 2023. Only a few drugs with this kind of revenue on earth and it's not a given they replace it by then.  Its highly unlikely they will with a single drug but they have a great pipeline so they will get through it IMO.  Maybe they have zero growth for a year or more?  You are being compensated for the risk now.  There is always a reason why a blue chip is on sale for an extended period of time.  In ABBV case it is extremely easy to research.  

I don't even own ABBV though I now regret I didn't grab the super sale 18 months ago.  I do own JNJ-PFE-MRK and a lot of BMY.  BMY is also discounted.  BMY has to show the market the money after their big merger.  They have considerable debt like ABBV. JNJ has one of the best credit ratings in the world.  We are pretty sure what their 2023 earnings look like so it is not extremely undervalued now.  We get paid to take risks.  If I don't bother to investigate the other major players in the sector I should buy a healthcare ETF.  You obviously watch the day to day moves on your stocks.  Knowledge keeps you from over-reacting to random sector moves that are going to happen for no obvious reason.  ABBV PE is nothing like 40 so you have work to do before you even comment on their valuation.

ChadR

New positions on AVAL and SJM.
(07-10-2021, 01:20 PM)fenders53 Wrote: [ -> ]Feel free to contradict me Eric.

Ken,

You seem willing to put in the analytics time and you should if you grow largish holdings in individual stocks.  This is a place to spend some time because a PE without context is just a number.

ABBV PE vs MSFT PE vs a REIT PE really is meaningless to an investor.  S&P500 PE numbers 2005-2015 vs today has some relevance.  It's highly likely historicals won't be completely ignored forever.  It's not a given 1990 will ever matter again though.  Don't hold you breath waiting for UTE PEs to return to 1980 levels.  The game changed.  1999 tech PEs were and still are nuts.  There are limits to valuation insanity that can't be explained away.  There is always context to consider.

Healthcare/pharma PEs would be a good place to learn.  First of all the entire sector is undervalued vs SPY.  There is risk they will be targeted by politicians from both parties.  That may or may not last for years.  Almost all the major pharmas are being discounted some for that.  As an ABBV shareholder you should be very aware their flagship drug comes off patent in 2023. Only a few drugs with this kind of revenue on earth and it's not a given they replace it by then.  Its highly unlikely they will with a single drug but they have a great pipeline so they will get through it IMO.  Maybe they have zero growth for a year or more?  You are being compensated for the risk now.  There is always a reason why a blue chip is on sale for an extended period of time.  In ABBV case it is extremely easy to research.  

I don't even own ABBV though I now regret I didn't grab the super sale 18 months ago.  I do own JNJ-PFE-MRK and a lot of BMY.  BMY is also discounted.  BMY has to show the market the money after their big merger.  They have considerable debt like ABBV. JNJ has one of the best credit ratings in the world.  We are pretty sure what their 2023 earnings look like so it is not extremely undervalued now.  We get paid to take risks.  If I don't bother to investigate the other major players in the sector I should buy a healthcare ETF.  You obviously watch the day to day moves on your stocks.  Knowledge keeps you from over-reacting to random sector moves that are going to happen for no obvious reason.  ABBV PE is nothing like 40 so you have work to do before you even comment on their valuation.

While I do know about the drug going off patent in 2023, the rest of the P/E conversation went over my head so, yeah, lots to learn there.  I was used to going to the stock profile and looking at the listed PE.  Clearly it's more nuanced than that.
[quote pid='27271' dateline='1626107287']
(07-10-2021, 01:20 PM)fenders53 Wrote: [ -> ]Feel free to contradict me Eric.

Ken,

You seem willing to put in the analytics time and you should if you grow largish holdings in individual stocks.  This is a place to spend some time because a PE without context is just a number.

ABBV PE vs MSFT PE vs a REIT PE really is meaningless to an investor.  S&P500 PE numbers 2005-2015 vs today has some relevance.  It's highly likely historicals won't be completely ignored forever.  It's not a given 1990 will ever matter again though.  Don't hold you breath waiting for UTE PEs to return to 1980 levels.  The game changed.  1999 tech PEs were and still are nuts.  There are limits to valuation insanity that can't be explained away.  There is always context to consider.

Healthcare/pharma PEs would be a good place to learn.  First of all the entire sector is undervalued vs SPY.  There is risk they will be targeted by politicians from both parties.  That may or may not last for years.  Almost all the major pharmas are being discounted some for that.  As an ABBV shareholder you should be very aware their flagship drug comes off patent in 2023. Only a few drugs with this kind of revenue on earth and it's not a given they replace it by then.  Its highly unlikely they will with a single drug but they have a great pipeline so they will get through it IMO.  Maybe they have zero growth for a year or more?  You are being compensated for the risk now.  There is always a reason why a blue chip is on sale for an extended period of time.  In ABBV case it is extremely easy to research.  

I don't even own ABBV though I now regret I didn't grab the super sale 18 months ago.  I do own JNJ-PFE-MRK and a lot of BMY.  BMY is also discounted.  BMY has to show the market the money after their big merger.  They have considerable debt like ABBV. JNJ has one of the best credit ratings in the world.  We are pretty sure what their 2023 earnings look like so it is not extremely undervalued now.  We get paid to take risks.  If I don't bother to investigate the other major players in the sector I should buy a healthcare ETF.  You obviously watch the day to day moves on your stocks.  Knowledge keeps you from over-reacting to random sector moves that are going to happen for no obvious reason.  ABBV PE is nothing like 40 so you have work to do before you even comment on their valuation.

While I do know about the drug going off patent in 2023, the rest of the P/E conversation went over my head so, yeah, lots to learn there.  I was used to going to the stock profile and looking at the listed PE.  Clearly it's more nuanced than that.
[/quote]
It's a necessary skill to have some concept of valuation if you are going to buy individual stocks.  Especially in a market with most sectors trending overvalued.  I do think it would be best if you start by looking at one sector.  The term "PEG" ratio might help you understand why some sectors have much different PEs.  You can always ask questions here.
ABBV forward PE is only 9.42. So its very cheap and still had a dividend yield of over 4%

You cant use current PE on any stock as that doesn't tell the story. When we buy a stock where not buying it for today, but for the future and long time. Isn't that the reason why we have this forum lol

I added to ABBV just now on ex-dividend day.
Also added a significant position in JEPI

And oil stocks are still very cheap when you use forward PE

CVX - 17 PE
EOG - 11 PE
XOM - 16 PE

MSFT PE 33 (so not bad for a tech name)
AVGO - 16
AAPL - 27
TSM - 31
AMAT - 18

Still a few under 20 with AMAT and AVGO. Just a few names to compare with

So there is some value in the market still. Just have to know where to find it.
PYPL – 63
SQ – 169
TXN – 26
CRM – 70
ADBE – 51
FB – 30
TTD – 180
NVDA – 52
NOW – 104
CRWD – 711
ETSY – 67
TTWO – 42
ENPH - 141

Some expensive names here. Gives you an idea that any hiccup with these names, and they will get punished. As of now I have no stocks with a PE over 30. That’s the way I’m playing the market going forward.
(07-13-2021, 10:17 AM)stockguru Wrote: [ -> ]PYPL – 63
SQ – 169
TXN – 26
CRM – 70
ADBE – 51
FB – 30
TTD – 180
NVDA – 52
NOW – 104
CRWD – 711
ETSY – 67
TTWO – 42
ENPH - 141

Some expensive names here. Gives you an idea that any hiccup with these names, and they will get punished. As of now I have no stocks with a PE over 30.  That’s the way I’m playing the market going forward.

Thanks for posting, This info is very helpful. It's like what I have been saying. The tech names are all priced for perfection. The day will come when they will collapse. Like you I have been buying the value names. Investors don't know how to figure out future PE. Most see the oil names with negative earnings and say they are over valued. I have been adding to both CVX and EOG. Banks have come down as well and I'm looking at some of the those names as well. WFC comes to mind.
The problem is even deeper than that. I agree rookie investors don't know how to analyze a PE. Their ignorance has paid off. Funds know better, but they roll with the game and feed the MO anyway because it's been working a very long time. They know when to trim. I get "scolded" here repeatedly for keeping 80% of my port extremely sane at all times. I've left easy money on the table and this foolishness could continue for another year or more. Be as sure as you like but you are just guessing in the near term. It's exactly why all my option sells are short term.

My SPEC game wound down to zero so gradually adjusting that. Sold a few spec puts today expiring fast. It works until it doesn't and they roll easy at least once.
(07-13-2021, 10:04 AM)Ïstockguru Wrote: [ -> ]ABBV forward PE is only 9.42. So its very cheap and still had a dividend yield of over 4%

You cant use current PE on any stock as that doesn't tell the story.  When we buy a stock where not buying it for today, but for the future and long time. Isn't that the reason why we have this forum lol

I added to ABBV just now on ex-dividend day.
Also added a significant position in JEPI

And oil stocks are still very cheap when you use forward PE

CVX - 17 PE
EOG - 11 PE
XOM - 16 PE

MSFT PE 33 (so not bad for a tech name)
AVGO - 16
AAPL - 27
TSM - 31
AMAT - 18

Still a few under 20 with AMAT and AVGO. Just a few names to compare with

So there is some value in the market still. Just have to know where to find it.

Never look closely at AMAT and it appears to be a good stock. I plan to increase my tech exposure so I would initiate a position on AMAT. Thanks for the tip.
The shares are never cheap enough for me so sold a few out of the money puts today. TTCF-CHWY and yet another AUG VSTO put. I am going to chill out on VSTO after the next earnings report. Only room for one or two more spec play in the port this month. VSTO isn't SPEC but I have added SPEC this week.
Used some pooled dividends to add another share of FISV in my ROTH.

Thought the chart looked like a decent place to add.

[attachment=282]
Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767